Q Biomed Inc., of New York, said it will work with Menlo Park, Calif.-based SRI International to provide formulation development, preclinical development and early clinical manufacturing of QBM-001, the company's preclinical program for autistic spectrum disorder drug development program for nonverbal or minimally verbal autistic children.